【摘要】 目的随访HBeAg阴性和HBeAg阳性慢性乙型肝炎的临床转归,为比较两者的预后提供佐证。方法采用回顾性分析.随访6～18年,平均(11.8±4.1)年,经肝穿刺病理组织学诊断,HBeAg阴性65例、HBeAg阳性118例慢性乙型肝炎患者的临床转归。统计学处理采用t检验和x~2检验。结果HBeAg阴性慢性乙型肝炎患者累汁发展为肝硬化7例。占10.8%,肝癌4例.占6.2%,死亡8例.占12.3%;HBeAg阳性慢性乙型肝炎患者累计发展为肝硬化15例.占12.7%,肝癌8例,占6.8%,死亡12例,占10.2%。两组相比,肝硬化、肝癌和死亡的发生率差异均无统汁学意义(均P>0.05)。结论HBeAg阴性和HBeAg阳性慢性乙型肝炎患者的远期临床转归差异无统计学意义。更多还原

【Abstract】 Objective To compare the long-term outcomes between hepatitis B e antigen (HBeAg)-negative chronic hepatitis B(e-CHB)and hepatitis B e antigen-positive chronic hepatitis B (e+CHB).Method The clinical prognosis of sixty-five e-CHB patients,mean age(31.9±8.0) years,male:female 52:13,and one hundred and eighteen e+CHB patients,mean age(31.1±7.2) years,male:female 100:18,diagnosed by biopsy were analysed by retrospective study.The mean follow-up time was(11.8±4.1)years.This study was focused on long-term clinical outcomes including the rate of liver cirrhosis(LC)and hepatocellular carcinoma(HCC)and death.Results In 65 e-CHB group,7(10.8%)developed LC,4(6.2%)developed HCC and 8(12.3%)died and the cumulative survival rates were 95.4%,90.4% and 86.7% in 5,10,15 years,respectively.In 118 e+ CHB group,15(12.7%)developed LC,8(6.8%)developed HCC and 12(10.2%)died and the cumulative survival rates were 97.5%,92.8% and 84.0% in 5,10,15 years,respectively.The rate of LC and HCC and death were not markedly different(P>0.05)between the two groups.Conclu- sion The long-term outcomes of e-CHB is not markedly different compared with that of e+CHB.更多还原